
News|Articles|July 1, 2002
LABELING UPDATE: CLASS study, updated GI, CV risk info, added to celecoxib label
Safety information from the Celecoxib Long-term Arthritis Safety Study (CLASS)on GI and cardiovascular events has been included in safety labeling forcelecoxib (Celebrex, Searle).
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
National Alliance survey shows employers are leaving the ‘big 3’ for other PBMs
2
7 takeaways from the MHE webinar on PBM reform and transparency
3
Novo Nordisk's ziltivekimab falls short to reduce cardiovascular events in phase 3 trial
4
Prior authorization isn’t shrinking. Its savings are
5





















